|
|
||||||||
precursor promote
iNOS expression in vascular smooth muscle cells
Division of Nephrology, Department of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, Massachusetts 02111
| |
ABSTRACT |
|---|
|
|
|---|
After injury to the blood vessel
wall, vascular smooth muscle cells (SMC) synthesize interleukin (IL)-1
and inducible nitric oxide (NO) synthase (iNOS). The present study
tested whether endogenous production of IL-1
stimulates iNOS
expression in vascular SMC, and assessed whether IL-1
exerts
autocrine effects on the cells producing IL-1
or juxtacrine effects
on cells that contact the IL-1
producing cells. Rat aortic SMC were
transiently transfected with expression plasmids encoding either
IL-1
precursor, which localizes to the plasma membrane, or mature
IL-1
, which remains cytosolic. iNOS mRNA levels, determined
by RT-PCR, and production of nitrite, a stable oxidation product of NO,
were markedly elevated in SMC overexpressing IL-1
precursor, and
modestly elevated in SMC overexpressing mature IL-1
, relative to SMC
transfected with vector alone. Exposure to exogenous IL-1
or TNF-
further stimulated iNOS gene expression in SMC producing IL-1
; low
levels of IL-1
(20 pg/ml) were effective in SMC transfected with
IL-1
precursor plasmid, whereas SMC transfected with mature IL-1
plasmid or vector alone required higher concentrations of IL-1
(200 and 2,000 pg/ml, respectively). The increases in iNOS mRNA levels and
NO production in SMC overexpressing IL-1
precursor were prevented by
exogenous IL-1 receptor antagonist, suggesting that these effects were
mediated by the type I IL-1 receptor. Immunostaining studies indicated
that IL-1
precursor stimulates iNOS gene expression via cell-cell
contact. Expression of iNOS was enhanced in cells that were in contact
with a cell overexpressing IL-1
precursor (identified by
coexpression of green fluorescent protein), and in cells that were
overexpressing IL-1
themselves, but only when the cell contacted
another cell. Together these results indicate that IL-1
precursor
acts by cell-cell contact as an autocrine and juxtacrine enhancer of
iNOS gene expression, inducing moderate iNOS expression on its own, and
markedly augmenting the responsiveness of rat aortic SMC to exogenous cytokines.
interleukin-1 receptor antagonist; tumor necrosis factor-
| |
INTRODUCTION |
|---|
|
|
|---|
INTIMAL HYPERPLASIA is a major clinical problem that limits the long-term efficacy of vascular procedures, such as balloon angioplasty and coronary bypass grafts, and a key component of this process is excessive vascular smooth muscle cell (SMC) proliferation (1, 38). The proliferative response evoked by vascular wall injury is preceded by a cascade of events, including synthesis of inducible nitric oxide (NO) synthase (iNOS), which likely modulates the extent of subsequent SMC proliferation. iNOS, like the constitutively expressed endothelial NOS (eNOS), produces NO via the five-electron oxidation of one of the guanidine nitrogens in L-arginine. However, distinct from eNOS, which is expressed in normal blood vessels and inhibits intimal proliferation evoked by vascular injury (34), it is not clear whether iNOS plays a pro- or antiproliferative role when expressed in injured blood vessels. NO, when added as a chemical NO donor or as NO gas, inhibits proliferation of SMC in vitro (18, 36, 33). However, NO has also been reported to stimulate SMC proliferation in vitro (20, 42), and neointima formation induced by mechanical injury is attenuated in iNOS knockout mice (13), suggesting iNOS may play a pro-proliferative role in this model.
Pro-inflammatory cytokines are the primary inducers of iNOS expression
in many cell types, including rat aortic SMC. Among those that induce
iNOS expression in rat aortic SMC in vitro, interleukin-1 (IL-1) is the
most potent (6). Several lines of evidence suggest that
SMC-derived IL-1 may be an important stimulus to iNOS expression in
SMC. Vascular SMC synthesize both
- and
-forms of IL-1 when
activated in vitro (7, 27, 44), and IL-1
is also
synthesized by smooth musclelike cells in clinically relevant intimal
hyperplastic lesions. IL-1
was detected by immunostaining in
spindle-shaped cells of saphenous vein bypass grafts that had become
stenotic, but not in internal mammary arteries that had remained
patent, or in normal arteries and veins (12). Also, a
recent study (5) indicates that low levels of IL-1
are
biologically active when produced endogenously by human vascular SMC.
IL-1
is synthesized as a 271-amino acid precursor molecule, which
lacks a classical signal sequence (15), and is not
efficiently released by cells, but nevertheless appears to be active in
its cell-associated form. In several cell types, including SMC, IL-1
precursor is thought to associate with the plasma membrane in a form
that can activate the type I IL-1 receptor on adjacent cells via
juxtacrine mechanisms (2, 22, 28). Recent studies have
suggested that the IL-1
precursor may also act within the cell, by a
mechanism involving direct localization to the nucleus (21, 30,
32, 46).
The present study determined whether endogenous production of IL-1
can induce iNOS gene expression in rat aortic SMC. Rat aortic SMC were
transiently transfected with expression plasmids, which direct the
production of either the precursor or mature form of IL-1
, and basal
and inducible expression of iNOS was assessed. Because mature IL-1
lacks the nuclear localization sequence, and putative membrane
localization signals that are present in the precursor molecule, and
does not localize to the nucleus (5, 30) or associate with
the plasma membrane (9, 11, 17), its expression should
reveal the effects that occur after cellular release. To distinguish
between autocrine versus juxtacrine actions of IL-1
precursor,
immunostaining was used to separately assess iNOS expression in
transfected cells themselves, and in those cells that contact a
transfected cell. The results indicate that IL-1
precursor is an
effective stimulus for iNOS gene expression in rat aortic SMC and can
also augment iNOS expression induced by exogenous cytokines. In
addition, juxtacrine effects appear to play a key role in the
biological activity of IL-1
precursor.
| |
METHODS |
|---|
|
|
|---|
Rat aortic SMC culture.
SMC were isolated from rat thoracic aorta by enzymatic dissociation as
described previously (8). SMC were cultured in growth media composed of DMEM supplemented with 10% FCS, glutamine,
penicillin, and streptomycin. Cells were passaged by harvesting with
tryspin-EDTA and used between passages 3 and 12. Rat aortic SMC
expressed
-actin, as determined by immunofluorescent staining
using mouse anti-
-actin-FITC conjugate (Sigma).
IL-1
expression plasmids.
IL-1
expression plasmids were constructed by PCR amplification of a
plasmid containing human IL-1
cDNA, cloned from LPS-activated human
peripheral blood cells (ATCC), as previously described
(5), and cloned into pcDNA3. The IL-1
precursor
expression plasmid encodes amino acids 1-271, whereas the mature
IL-1
expression plasmid encodes amino acids 113-271, both
cloned downstream of an introduced Kozak consensus sequence.
Transfection of rat aortic SMC by electroporation.
Rat aortic SMC (5 × 106/condition) were transfected
by electroporation with pcDNA3 alone or encoding IL-1
precursor or
mature IL-1
at 300 V and 960 µF (Genepulser, Bio-Rad). Cells were
then plated and incubated overnight in media supplemented with sodium butyrate (5 mM) and then washed, and fresh media were added to the
cells. In some studies, stable transfectants expressing the neomycin
resistance gene in pcDNA3 were selected by supplementing the growth
media with 200 µg/ml of Geneticin (Sigma; St. Louis, MO). Experiments
were conducted after 4 wk of selection.
IL-1
enzyme immunometric assay.
Cell lysates were prepared by three successive freeze-thaw cycles in
buffer containing 10 mM sodium phosphate, 0.15 M NaCl, 0.25% BSA, and
0.05% sodium azide and were cleared by centrifugation at 500 g for 10 min. Immunoreactive IL-1
in cell lysates was measured by an enzyme immunometric assay (EIA) that is specific for
both the precursor and mature forms of human IL-1
(Cayman Chemical;
Ann Arbor, MI).
RT-PCR analysis.
Total RNA was isolated by using RNAzol B (Biotecx Laboratories;
Houston, TX). RNA (2 µg) was reverse-transcribed for 1 h at 37°C with 200 units of Moloney murine leukemia virus RT (GIBCO-BRL), by using an oligo (dT) primer and the buffer supplied by the
manufacturer, in a total volume of 20 µl. The reaction was
terminated by heating to 95°C for 5 min, and 2 µl of this first
strand cDNA was added to each PCR reaction. The PCR mixes contained 50 mM KCl, 10 mM Tris · HCl (pH 8.3), 1 mM MgCl2, 0.01 mg/ml gelatin, 200 µM of each dNTP, 250 nM of each primer, and 1 U
Taq DNA polymerase (GIBCO-BRL) in a 20 µl volume. The
primers used to amplify iNOS mRNA were 5'-TAGAGGAACATCTGGCCAGG-3' and
5'-TGGCCGACCTGATGTTGCCA-3' (sense and antisense, respectively). The
primers for the housekeeping gene
-actin were
5'-TCCTAGCACCATGAAGATC-3' and 5'-AAACGCAGCTCAGTAACAG-3'. Amplification
was performed as previously described (7), with annealing
temperatures of 57 and 50°C for iNOS and
-actin primers, respectively. Each sample was amplified for 25-30 cycles with iNOS
primers, and for 18-20 cycles with
-actin primers (within the
exponential range of amplification for each product). Products were
size separated by electrophoresis in a 5% polyacrylamide gel and
visualized by ethidium bromide staining.
Nitrite assay. Aliquots of cell supernatants were assayed for nitrite by using a standard protocol in which samples were mixed with an equal volume of Greiss reagent (0.05% N-(1-Naphthyl)ethylenedamine dihydrochloride, 0.5% sulfanilamide, and 2.5% phosphoric acid) and incubated at room temperature for 10 min (19). The absorbance at 550 nm was measured, and nitrite concentration was determined by using sodium nitrite diluted in media as standards. Nitrite concentrations of the media were normalized to cell number, as determined by Coulter counter analysis.
Localization of iNOS expression in nontransfected and transfected
rat aortic SMC cocultures.
Rat aortic SMC were cotransfected, as described above for single
plasmid transfections, with 10 µg pEGFP (Clontech), which encodes
green fluorescent protein (GFP) and serves as a marker of transfected
cells, and 20 µg pcDNA3 alone or encoding IL-1
precursor or mature
IL-1
. After electroporation was completed, 50,000 nontransfected SMC
and 50,000 transfected SMC were plated together in 60-mm plates
containing glass coverslips. Cells were then incubated
overnight in media supplemented with sodium butyrate, 24 h in
fresh media alone, and an additional 24 h in media with or without
IL-1
(2 ng/ml). iNOS protein was localized in SMC cocultures by
indirect immunofluorescence staining. Cells were washed in PBS, fixed
in 3.7% formaldehyde (15 min), and permeabilized in 0.2% Triton
X-100/PBS (5 min). Nonspecific binding sites were blocked with 10%
normal horse serum, and the cells were incubated for 1 h at 37°C
with polyclonal rabbit antiserum specific for murine macrophage iNOS
(Cayman Chemical; Ann Arbor, MI) and then 45 min at room temperature
with Texas-Red-coupled donkey anti-rabbit IgG (Jackson Immunoresearch).
Cells were then incubated with Hoechst 33342 to stain cell nuclei,
mounted in 90% glycerol/PBS, and observed through a microscope
(Diaphot-TMD, Nikon) equipped with epifluorescence. The presence of
iNOS was evaluated in transfected cells (GFP positive), in
nontransfected cells (GFP negative) that were in direct contact with a
transfected cell, and in cells that were neither transfected nor in
direct contact with any other cell. For each treatment group, 300 cells
(100 of each subgroup) were analyzed. The observer performing the
analysis was blinded with respect to the specimen treatment.
Statistical analysis. The significance of treatment-induced differences was determined either by Student's t-test or by ANOVA, followed by Dunnett's procedure to compare multiple means with a similar control value. P < 0.05 was considered statistically significant.
| |
RESULTS |
|---|
|
|
|---|
iNOS gene expression is enhanced in rat aortic SMC transfected with
IL-1
expression plasmids.
Transient overexpression of either IL-1
precursor or mature IL-1
induced iNOS gene expression in rat aortic SMC. iNOS mRNA was not
detectable by RT-PCR analysis in SMC transfected with vector alone,
either 72 or 96 h after transfection (Fig.
1A). In contrast, iNOS mRNA
was present in SMC that had been transfected with either IL-1
precursor or mature IL-1
expression plasmids. At both time points,
the levels of iNOS mRNA were greater in SMC overexpressing IL-1
precursor compared with SMC overexpressing mature IL-1
. To assess
whether increased levels of iNOS mRNA were associated with increased
iNOS activity, the levels of nitrite, a stable NO oxidation product,
were measured in the supernatants, which overlayed the cells from
72-96 h after transfection. Nitrite production was significantly
elevated in rat aortic SMC overexpressing either form of IL-1
relative to those transfected with vector alone, and SMC overexpressing
IL-1
precursor produced more nitrite than SMC overexpressing mature
IL-1
(Fig. 1B). The levels of nitrite produced by SMC
overexpressing IL-1
precursor were low, however, accumulating to
only 2-3 µM in 24 h relative to levels of 20-35 µM,
which are reached after stimulation with exogenous IL-1
(6). Nitrite production was also increased in SMC that were stably transfected with IL-1
precursor expression plasmid (4.45 ± 1.32 µM/24 h per 105 cells) relative to SMC
stably transfected with vector alone (0.81 ± 0.29 µM/24 h per
105 cells; P < 0.05).
|
precursor, relative to SMC overexpressing mature IL-1
. The
enhanced efficacy of IL-1
precursor relative to mature IL-1
was
not due to higher expression levels after transfection. In a previous
study (5), IL-1
precursor and mature IL-1
were expressed at similar levels after transient transfection of a rat
aortic SMC line with the corresponding expression plasmid, as indicated
by Western blot analysis. Also, in the present study, rat aortic SMC
transfected with IL-1
precursor expression plasmid produced less
IL-1
(231 ± 51 pg/105 cells) relative to those
transfected with mature IL-1
expression plasmid (475 ± 74 pg/105 cells), as determined by a specific immunoassay.
Thus the greater efficacy of the IL-1
precursor expression plasmid
was not due to higher expression levels.
Exogenous IL-1 receptor antagonist abolishes induction of iNOS in
rat aortic SMC overexpressing IL-1
precursor.
The greater efficacy of IL-1
precursor, compared with mature
IL-1
, may be attributable to localization of the precursor molecule
to the nucleus or to the plasma membrane, properties that are not
shared by the mature IL-1
molecule. Effects of membrane-associated IL-1
precursor are mediated by the type I IL-1 receptor and are inhibited by high concentrations of exogenous IL-1 receptor antagonist (IL-1RA; 22), in contrast to the direct nuclear actions of IL-1
, which are thought to occur independently of this receptor (30, 32). To distinguish between these two mechanisms, the ability of
exogenous IL-1RA to attenuate iNOS induction in rat aortic SMC
overexpressing IL-1
precursor was assessed. Addition of exogenous IL-1RA (10 µg/ml) to the cell culture media immediately after transfection prevented the subsequent induction of iNOS by expression of IL-1
precursor. iNOS mRNA was not detectable by RT-PCR in SMC
overexpressing IL-1
precursor and incubated in the presence of
exogenous IL-1RA, whereas iNOS PCR product was apparent in SMC
overexpressing IL-1
precursor and incubated without IL-1RA (Fig.
2A). Also, nitrite production
was not enhanced in SMC overexpressing the IL-1
precursor that were
incubated in the presence of IL-1RA but was significantly enhanced in
SMC overexpressing IL-1
precursor incubated in the absence of IL-1RA
(Fig. 2B). These results indicate that IL-1
precursor
acts extracellularly to stimulate iNOS gene expression via activation
of the type I IL-1 receptor.
|
Increased sensitivity to exogenous IL-1
and TNF-
in rat
aortic SMC overexpressing IL-1
.
Exogenous IL-1
and TNF-
can act synergistically to induce iNOS
expression in rat aortic SMC (6). Therefore, the ability of IL-1
produced by rat aortic SMC to act synergistically with exogenous IL-1
or TNF-
and induce iNOS activity was assessed. Exposure to exogenous IL-1
induced NO production in nontransfected and pcDNA3-transfected rat aortic SMC; however, a high concentration of
IL-1
(2,000 pg/ml) was required to significantly stimulate nitrite
production in both groups (Fig.
3A), as previously described (6). SMC transfected with IL-1
precursor expression
plasmids produced significant nitrite in the absence of exogenous
cytokine stimulation, as described above (Figs. 1B and
2B), and nitrite production was further enhanced by
exposure to exogenous IL-1
, even at concentrations as low as 20 pg/ml. Although SMC overexpressing mature IL-1
did not produce
nitrite in the absence of exogenous IL-1
stimulation, sensitivity to
exogenous IL-1
was enhanced relative to SMC transfected with vector
alone. SMC overexpressing mature IL-1
were not as sensitive
to exogenous IL-1
as cells that overexpressed IL-1
precursor;
significant stimulation of nitrite production required exposure to 200 pg/ml IL-1
, 10-fold more exogenous IL-1
than that required to
stimulate nitrite production in rat aortic SMC overexpressing IL-1
precursor.
|
(50 ng/ml) did not
induce significant NO production in either nontransfected or
pcDNA3-transfected SMC (Fig. 3B). However, exogenous TNF-
(0.5-50 ng/ml) stimulated nitrite production in a
concentration-dependent manner in SMC overexpressing either form of
IL-1
. SMC overexpressing IL-1
precursor produced more nitrite
than SMC overexpressing mature IL-1
at each concentration of TNF-
that was tested.
IL-1
precursor stimulates iNOS expression in rat aortic SMC via
juxtacrine effects.
Studies with IL-1RA indicated that the action of IL-1
precursor was
extracellular and involved the type I IL-1 receptor. To assess the role
of juxtacrine effects in the action of IL-1
precursor,
immunostaining studies were conducted to localize iNOS expression in
cocultures of SMC, which contained a mixture of transfected and
nontransfected SMC. Rat aortic SMC were cotransfected with an
IL-1
expression plasmid and an expression plasmid encoding GFP, as a marker of transfected cells. In preliminary studies, iNOS
protein was not detectable by indirect immunofluorescence staining in
SMC overexpressing IL-1
precursor in the absence of stimulation with
exogenous cytokine, even though the cells expressed detectable iNOS
mRNA and produced detectable nitrite (Figs. 1-3). The
absence of detectable iNOS protein may be due to a lower sensitivity of
the immunostaining procedure compared with the higher sensitivities of
the RT-PCR and nitrite assays. This hypothesis was supported by
subsequent experiments, in which iNOS protein was detectable in SMC
exposed to exogenous IL-1
, a stimulus that induces higher levels of
nitrite production than overexpression of IL-1
precursor
(6). Surprisingly, however, <10% of nontransfected SMC
expressed detectable iNOS protein after exposure to exogenous IL-1
(1 ng/ml), indicating an inherent variability of rat aortic SMC
subpopulations in their sensitivity to exogenous IL-1
.
precursor produced significantly higher
levels of nitrite when stimulated with exogenous IL-1
, relative to
nontransfected SMC or SMC transfected with vector alone, as shown in
Fig. 3A. To analyze the spatial distribution of exogenous IL-1
-induced iNOS expression relative to the location of transfected cells, iNOS expression was assessed by immunostaining and scored in
three different subpopulations of cells within the rat aortic SMC
cocultures: cells that were transfected themselves (GFP positive), cells that were not transfected (GFP negative) but were in direct contact with a transfected cell, and nontransfected cells that were not
in direct contact with any other cell (Fig
4). Immunoreactive iNOS was detectable in
a small percentage of cells (
10%) within the pcDNA3-transfected rat
aortic SMC cocultures, and this percentage was similar in all three
subgroups: transfected cells, nontransfected cells that contacted a
transfected cell, and nontransfected cells that were isolated from any
other cell. The percentage of iNOS-positive cells was also low in all
three subgroups of rat aortic SMC cultures, which contained cells
overexpressing mature IL-1
. In contrast, the percentage of
iNOS-positive cells was significantly greater in rat aortic SMC
cocultures that contained cells overexpressing IL-1
precursor. Specifically, iNOS staining was increased in rat
aortic SMC transfected with IL-1
precursor expression plasmid and in
nontransfected rat aortic SMC in direct contact with a cell
overexpressing IL-1
precursor (Fig.
5). Cells that were not transfected and
were isolated from other rat aortic SMC did not have enhanced
expression of immunoreactive iNOS. These results indicate that IL-1
precursor can enhance iNOS gene expression via autocrine and juxtacrine
effects and suggest that cell-cell contact plays a crucial role in
IL-1
precursor action. An additional study with a similar protocol
further analyzed the induction of iNOS in rat aortic SMC transfected
with IL-1
precursor expression plasmids. Expression of iNOS protein
was increased in rat aortic SMC transfected with IL-1
precursor
expression plasmid relative to rat aortic SMC transfected with vector
alone, when transfected cells that were in contact with another cell
were analyzed (16 and 1%, respectively, iNOS positive). In contrast,
iNOS expression was not enhanced in rat aortic SMC transfected with
IL-1
precursor expression plasmid relative to rat aortic SMC
transfected with vector alone when transfected cells that were isolated
were analyzed (4 and 10%, respectively, iNOS positive).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The proliferation and function of cells in animal tissues are
controlled by several forms of intercellular communication. The ability
of diffusible polypeptide factors to activate membrane receptors and
induce signals that influence cell function is well established.
Membrane-anchored ligands can also activate receptors; however, this
form of communication requires direct cell-cell contact
(10). IL-1
precursor is one example of a polypeptide factor that has been proposed to act as a membrane-associated ligand
that activates cells via cell-cell contact (2, 17, 22, 25,
28). The present studies have three principal findings. First,
they indicate that endogenous production of IL-1
precursor, as a
sole stimulus, can induce iNOS gene expression and NO production in rat
aortic SMC. Second, endogenous production of IL-1
precursor also
sensitizes rat aortic SMC to the stimulatory effects of exogenous proinflammatory cytokines, including IL-1
and TNF-
. Finally, the primary mechanism of IL-1
precursor action involves juxtacrine effects, which are exerted via cell-cell contact, and involves activation of the type I IL-1 receptor.
Endogenous production of IL-1
precursor was a sufficient stimulus to
induce detectable expression of iNOS in rat aortic SMC. Both iNOS mRNA
and the release of nitrite, a stable NO oxidation product, were
detectable in rat aortic SMC overexpressing IL-1
precursor either
transiently or stably; however, the level of extracellular nitrite
accumulation was low (~2 µM) relative to the nitrite levels found
when rat aortic SMC are stimulated with exogenous IL-1
(~25 µM;
Ref. 6). In previous studies (6), IL-1
and
TNF-
, when added as soluble factors, acted synergistically to induce
iNOS gene expression. In the present study, low levels of IL-1
and
TNF-
(pg/ml) stimulated NO production in rat aortic SMC, which were
producing IL-1
precursor. In contrast, higher levels of exogenous
IL-1
(ng/ml) were required to induce NO production in the absence of
endogenous IL-1
synthesis, and high concentrations of TNF-
were not effective. These results indicate that IL-1
precursor that
is produced endogenously by rat aortic SMC can synergize with exogenous
IL-1
or TNF-
to induce iNOS gene expression in SMC.
One mechanism by which IL-1
could exert local effects on gene
expression is by acting as a soluble mediator after release from the
cell. IL-1
precursor and mature IL-1
are equipotent agonists of
the type I IL-1 receptor when presented to IL-1 receptor expressing
cells as soluble factors (35). Also, both the precursor and mature forms of IL-1
can be released from cells (26, 39, 45), although both forms lack a signal sequence for secretion via classical pathways, and the secretory mechanism for both proteins is unknown. However, mature IL-1
appears to be the
preferentially released form, on the basis of studies with human
monocytes and bladder carcinoma cells (39, 45). Therefore,
if IL-1
acted as a soluble extracellular factor after release from
rat aortic SMC, then one would predict that overexpression of mature
IL-1
would induce iNOS gene expression more effectively than
overexpression of IL-1
precursor. In contrast, in the present
studies overexpression of IL-1
precursor consistently induced higher
levels of iNOS gene expression than overexpression of mature IL-1
.
Therefore, the enhanced effectiveness of IL-1
precursor observed in
this study argues against a primary mechanism involving cellular
release of soluble IL-1
.
A second mechanism by which IL-1
could induce iNOS gene expression
in rat aortic SMC is as a membrane-associated ligand. IL-1
precursor
localizes to the plasma membrane after synthesis in LPS-stimulated
cells (14, 41, 49), where it remains associated with the
cell surface and is thought to activate the type I IL-1 receptor on
adjacent cells via juxtacrine mechanisms (2, 17, 22, 25,
28). In contrast, mature IL-1
does not associate with the
cell surface (9, 11, 17). In the present study, addition
of IL-1RA, a competitive antagonist of IL-1 binding to the type I IL-1
receptor (31), abolished expression of iNOS in SMC
transfected with IL-1
precursor expression plasmids. These results
support an extracellular site of action involving the type I IL-1
receptor. Immunostaining studies also supported the hypothesis that
IL-1
associates with the surface of rat aortic SMC in a form that
can activate type I IL-1 receptors via cell-to-cell contact. Cells in
contact with IL-1
-precursor overexpressing cells demonstrated
induction of iNOS, whereas isolated cells did not, indicating an
important role of juxtacrine stimulation. iNOS expression was also
enhanced in those SMC that were transfected with IL-1
precursor
expression plasmids, however, only when the cell was in direct contact
with another cell. It is possible that this effect involves two-way
communication between SMC, which are in contact with each other.
Because IL-1 is known to induce its own synthesis (43),
membrane expression of IL-1
in the transfected cell could induce
membrane expression of IL-1
in an adjacent cell, which in turn
induces expression of iNOS in the transfected cell. Alternatively, it
is possible that binding of IL-1
precursor to the type I IL-1
receptor on the adjacent cell elicits signal transduction events in the
IL-1
precursor expressing cells as well as in the adjacent cell.
This possibility has been proposed for juxtacrine mediators, which
contain transmembrane domains (10). However, IL-1
precursor lacks a transmembrane domain, thus a mechanism by which
IL-1
binding to its receptor could influence the IL-1
precursor
expressing cell is not clear.
IL-1
precursor has also been proposed to act within the cell in some
cell types, via a mechanism that is independent of the type I IL-1
receptor and involves direct localization to the nucleus (21, 30,
32, 46). In human vascular SMC and endothelial cells transfected
with the corresponding expression plasmid, IL-1
precursor localizes
to the nucleus, whereas mature IL-1
remains in the cytosol (5,
30, 46). The action of IL-1
precursor was linked to its
nuclear localization in two studies with human endothelial cell lines.
In one study, stable expression of IL-1
precursor stimulated
expression of IL-1-inducible genes and inhibited cellular
proliferation, whereas stable expression of mature IL-1
was
ineffective (30). In the second study, stable expression of IL-1
precursor inhibited cell migration, whereas stable
expression of mature IL-1
, or a nuclear localization deficient
mutant of IL-1
precursor, stimulated cell migration
(32). In both studies, the fact that exogenous IL-1RA did
not reverse the effects of IL-1
precursor expression was used as
evidence that IL-1
precursor acts within cells. In the present
study, exogenous IL-1 receptor antagonist abolished iNOS expression in
rat aortic SMC overexpressing IL-1
precursor, arguing against a role
of nuclear localization in IL-1
precursor induced iNOS gene
expression. The ineffectiveness of IL-1RA in previous studies could be
due to the fact that lower IL-1RA concentrations were used (100 ng/ml).
The present study used 10 µg/ml IL-1RA on the basis of evidence that
higher concentrations are required to inhibit membrane-associated
IL-1
activity (22). Alternatively, the short incubation
with exogenous IL-1RA (20-24 h) may not have been sufficient time
to reverse the long-term effects in stable transfectants that had been
producing IL-1
precursor for many weeks. In support of this
interpretation, the mitogenic effects of long term IL-1 exposure in
human SMC are only partially reversed by a 72-h exposure to IL-1RA
(5). It is possible that localization to the plasma
membrane, rather than to the nucleus, also accounts for the actions of
IL-1
precursor in human endothelial cells (30, 32).
Several lines of evidence indicate that SMC-derived iNOS contributes to the modulation of SMC proliferation in pathophysiological states. However, iNOS may limit or promote intimal hyperplasia, depending on the pathological condition involved. Vascular SMC within balloon-injured rat carotid arteries express iNOS (47), and targeted deletion of the iNOS gene in mice is associated with a decrease in neointimal thickening after mechanical injury to the carotid artery (13), consistent with a pro-proliferative role of iNOS. In distinct contrast, other studies indicate that iNOS limits SMC proliferation, which occurs in coronary vessels after cardiac transplantation. iNOS is expressed by SMC within coronary arteries of transplanted human hearts that exhibit accelerated graft arteriosclerosis (37). Also, the accelerated arteriosclerosis that occurs after allogeneic cardiac transplantation is exacerbated in iNOS-deficient mice (24), indicating a protective role of the enzyme in limiting excessive SMC proliferation in the setting of transplant rejection. iNOS is also expressed by SMC within atherosclerotic lesions of the human aorta (29). However, whether iNOS plays a protective or deleterious role in atherosclerosis remains to be established.
Expression of iNOS in vascular SMC has also been proposed to contribute
to vasodilatation that occurs during sepsis (8). Exposure
of intact rat aortic segments to bacterial lipopolysaccharide (LPS) or
IL-1 in vitro markedly inhibits vascular contraction, an effect that is
independent of the endothelium and involves expression of iNOS
(3, 4, 6, 16). iNOS is also expressed in rat aorta after
injection of bacterial LPS in vivo (6); however,
immunostaining studies indicated that iNOS protein is expressed
primarily in adventitial fibroblasts, whereas iNOS expression was not
detectable in medial SMC (48). The adventitia may also be
the primary source of NO in intact rat aortic segments exposed to LPS
in vitro, on the basis of evidence that intact rat aortic segments
produce more NO after LPS stimulation than do segments of rat aortic
media from which the adventitia was removed (23). In the
present study, rat aortic SMC were obtained by enzymatic digestion of
the aortic media after separation from the adventitia, and a
subpopulation of cells that subsequently grew in culture expressed high
levels of iNOS protein after stimulation with exogenous IL-1
.
Another subpopulation of rat aortic SMC showed high levels of iNOS
protein when activated by two stimuli, soluble IL-1
and membrane-associated IL-1
precursor. SMC derived from enzymatic digestion of the media of many blood vessels, including the rat aorta
(40), are known to be heterogeneous with respect to
phenotype. Another aspect of this heterogeneity may be the endogenous
production of IL-1
, or alternatively IL-1
or TNF-
. The present
study indicates that differential endogenous production of IL-1
in
rat aortic SMC subpopulations may account for differential sensitivity
to exogenous cytokines.
The present study provides evidence that endogenous production of
IL-1
precursor can induce low-level iNOS gene expression in rat
aortic SMC and can act synergistically with exogenous IL-1
and
TNF-
to induce high-level iNOS expression. A primary mechanism of
IL-1
precursor action involves juxatacrine effects that are exerted
via cell-cell contact and are mediated via activation of the type I
IL-1 receptor. SMC-derived IL-1
precursor may be a clinically
relevant stimulus to iNOS expression in SMC and may contribute to the
development of intimal hyperplastic lesions in injured blood vessels or
transplanted hearts.
| |
ACKNOWLEDGEMENTS |
|---|
The authors acknowledge Tawnya Gannon for technical assistance.
Human recombinant IL-1
was provided by Dr. Richard Dondero (Cistron
Biotechnology; Pine Brook, NJ), and human recombinant IL-1RA was
provided by Dr. Charles A. Dinarello (University of Colorado; Denver, CO).
| |
FOOTNOTES |
|---|
This work was supported by National Heart, Lung, and Blood Institute Grant HL-47569.
Address for reprint requests and other correspondence: D. Beasley, New England Medical Center, PO Box 172, 750 Washington St., Boston, MA 02111 (E-mail: Dbeasley{at}Lifespan.org).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 28 July 2000; accepted in final form 13 November 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Austin, GE,
Ratliff NB,
Hollman J,
Tabei S,
and
Phillips DF.
Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery restenosis after percutaneous transluminal coronary angioplasty.
J Am Coll Cardiol
6:
369-375,
1985[Abstract].
2.
Bailly, S,
Ferrua B,
Fay M,
and
Gougerot-Pocidalo MA.
Paraformaldehyde fixation of LPS-stimulated human monocytes: technical parameters permitting the study of membrane IL-1 activity.
Eur Cytokine Netw
1:
47-51,
1990[Medline].
3.
Beasley, D.
Interleukin 1 and endotoxin activate soluble guanylate cyclase in vascular smooth muscle.
Am J Physiol Regulatory Integrative Comp Physiol
259:
R38-R44,
1990
4.
Beasley, D,
Cohen RA,
and
Levinsky NG.
Interleukin 1 inhibits contraction of vascular smooth muscle.
J Clin Invest
83:
331-335,
1989.
5.
Beasley, D,
and
Cooper A.
Constitutive expression of interleukin-1
precursor promotes human vascular smooth muscle cell proliferation.
Am J Physiol Heart Circ Physiol
276:
H901-H912,
1999
6.
Beasley, D,
and
Eldridge M.
Interleukin-1
and tumor necrosis factor-
synergistically induce NO synthase in rat vascular smooth muscle cells.
Am J Physiol Regulatory Integrative Comp Physiol
266:
R1197-R1203,
1994
7.
Beasley, D,
McGuiggin M,
and
Dinarello CA.
Human vascular smooth muscle cells produce an intracellular form of interleukin-1 receptor antagonist.
Am J Physiol Cell Physiol
269:
C961-C968,
1995
8.
Beasley, D,
Schwartz JH,
and
Brenner BM.
Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells.
J Clin Invest
87:
602-608,
1991.
9.
Beuscher, H,
Fallon R,
and
Colten H.
Macrophage membrane interleukin 1 regulates the expression of acute phase proteins in human hepatoma hep 3B cells.
J Immunol
139:
1896-1901,
1987[Abstract].
10.
Bosenberg, MW,
and
Massague J.
Juxtacrine cell signaling molecules.
Curr Biol
5:
832-838,
1993.
11.
Brody, D,
and
Durum S.
Membrane IL-1: IL-1
precursor binds to the plasma membrane via a lectin-like interaction.
J Immunol
143:
1183-1187,
1989[Abstract].
12.
Brody, JI,
Pickering NJ,
Capuzzi DM,
Fink GB,
Can CA,
and
Gomez F.
Interleukin-1
as a factor in occlusive vascular disease.
Am J Clin Pathol
97:
8-13,
1992[ISI][Medline].
13.
Chyu, KY,
Dimayuga P,
Zhu J,
Nilsson J,
Kaul S,
Shah PK,
and
Cercek B.
Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice.
Circ Res
85:
1192-1198,
1999
14.
Conlon, PJ,
Grabstein KH,
Alpert A,
Prickett KS,
Hopp TP,
and
Gillis S.
Localization of human mononuclear cell interleukin 1.
J Immunol
139:
98-102,
1987[Abstract].
15.
Dinarello, CA.
Biologic basis for interleukin-1 in disease.
Blood
87:
2095-2147,
1996
16.
French, JF,
Lambert LE,
and
Dage RC.
Nitric oxide synthase inhibitors inhibit interleukin-1
-induced depression of vascular smooth muscle.
J Pharmacol Exp Ther
259:
260-264,
1991
17.
Fuhlbrigge, RC,
Fine S,
Unanue E,
and
Chaplin D.
Expression of membrane interleukin 1 by fibroblasts transfected with murine pro-interleukin 1
cDNA.
Proc Natl Acad Sci USA
85:
5649-5653,
1988
18.
Garg, UC,
and
Hassid A.
Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.
J Clin Invest
83:
1774-1777,
1989.
19.
Green, LC,
Wagner DA,
Glogowski J,
Skipper PL,
Wishnok JS,
and
Tannebaum SR.
Analysis of nitrate, nitrite and [15N] nitrate in biological fluids.
Anal Biochem
126:
131-138,
1982[ISI][Medline].
20.
Hassid, A,
Arabshari H,
Bourcier T,
Dhaunsi GS,
and
Matthews C.
Nitric oxide selectively amplifies FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells.
Am J Physiol Heart Circ Physiol
267:
H1040-H1048,
1994
21.
Hofmeister, R,
Mannel DN,
and
Falk W.
Evidence for an intracellular activation loop in the IL-1 system.
J Inflamm
47:
151-163,
1997.
22.
Kaplanski, G,
Farnarier C,
Kaplanski S,
Porat R,
Shapiro L,
Bongrand P,
and
Dinarello C.
Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism.
Blood
84:
1-7,
1994
23.
Kleschyov, AL,
Muller B,
Schott C,
and
Stoclet JC.
Role of adventitial nitric oxide in vascular hyporeactivity induced by lipopolysaccharide in rat aorta.
Br J Pharmacol
124:
623-626,
1998[ISI][Medline].
24.
Koglin, J,
Glysing-Jensen T,
Mudgett JS,
and
Russell ME.
Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice.
Circulation
97:
2059-2065,
1998
25.
Kurt-Jones, EA,
Beller DI,
Mizel SB,
and
Unanue ER.
Identification of a membrane-associated interleukin-1 in macrophages.
Proc Natl Acad Sci USA
82:
1204-1208,
1985
26.
Lee, RT,
Briggs WH,
Cheng GC,
Rossiter HB,
Libby P,
and
Kupper T.
Mechanical deformation promotes secretion of IL-1
and IL-1 receptor antagonist.
J Immunol
159:
5084-5088,
1997[Abstract].
27.
Libby, P,
Ordovas JM,
Birinyi LK,
and
Dinarello CA.
Inducible interleukin-1 gene expression in human vascular smooth muscle cells.
J Clin Invest
78:
1432-1438,
1986.
28.
Loppnow, H,
and
Libby P.
Functional significance of human vascular smooth muscle cell-derived interleukin-1 in paracrine and autocrine regulation pathways.
Exp Cell Res
198:
283-290,
1992[ISI][Medline].
29.
Luoma, JS,
Stralin P,
Marklund SL,
Hiltunen TP,
Sarkioja T,
and
Yla-Herttuala S.
Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions. Colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins.
Arterioscler Thromb Vasc Biol
18:
157-167,
1998
30.
Maier, JAM,
Statuto M,
and
Ragnotti G.
Endogenous interleukin 1 alpha must be transported to the nucleus to exerts its activity in human endothelial cells.
Mol Cell Biol
14:
1845-1851,
1994
31.
McIntyre, KW,
Stepan GJ,
Kolinsky KD,
Benjamin WR,
Plocinski JM,
Kaffka KL,
Campen CA,
Chizzonite RA,
and
Kilian PL.
Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
J Exp Med
173:
931-939,
1991
32.
McMahon, GA,
Garfinkel S,
Prudovsky I,
Hu X,
and
Maciag T.
Intracellular precursor interleukin (IL)-1
, but not mature IL-1
, is able to regulate human endothelial cell migration in vitro.
J Biol Chem
272:
28202-28205,
1997
33.
Mooradian, DL,
Hutsell TC,
and
Keefer LK.
Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro.
J Cardiovasc Pharmacol
25:
674-678,
1995[ISI][Medline].
34.
Moroi, M,
Zhang L,
Yasuda T,
Virmani R,
Gold HK,
Fishman MC,
and
Huang PL.
Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice.
J Clin Invest
101:
1225-1232,
1998[ISI][Medline].
35.
Mosley, B,
Urdal DL,
Prickett KS,
Larsen A,
Cosman D,
Conlon PJ,
Gillis S,
and
Dower SK.
The interleukin-1 receptor binds the human interleukin-1
precursor but not the interleukin-1
precursor.
J Biol Chem
262:
2941-2944,
1987
36.
Nakaki, T,
Nakayama M,
and
Kato R.
Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells.
Eur J Pharmacol
189:
347-353,
1990[ISI][Medline].
37.
Ravalli, S,
Albala A,
Ming M,
Szabolcs M,
Barbone A,
Michler RE,
and
Cannon PJ.
Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease.
Circulation
97:
2338-2345,
1998
38.
Schwartz, SM,
deBlois D,
and
O'Brien ERM
The intima: soil for atherosclerosis and restenosis.
Circ Res
77:
445-465,
1995
39.
Siders, W,
Klimovitz J,
and
Mizel S.
Characterization of the structural requirements and cell type specificity of IL-1
and IL-1
secretion.
J Biol Chem
268:
22170-22174,
1993
40.
Skalli, O,
Ropraz P,
Trzeciak A,
Benzonana G,
Gillessen D,
and
Gabbiani G.
A monoclonal antibody against
-smooth muscle actin: a new probe for smooth muscle cell differentiation.
J Cell Biol
103:
2787-2796,
1986
41.
Stevenson, F,
Torrano F,
Locksley R,
and
Lovett D.
Interleukin 1: the patterns of translation and intracellular distribution support alternative secretory mechanisms.
J Cell Physiol
152:
223-231,
1992[ISI][Medline].
42.
Thomae, KR,
Nakayama DK,
Billiar TR,
Simmons RL,
Pitt BR,
and
Davies P.
The effect of nitric oxide on fetal pulmonary artery smooth muscle growth.
J Surg Res
59:
337-343,
1995[ISI][Medline].
43.
Warner, SJ,
Auger KR,
and
Libby P.
Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells.
J Exp Med
165:
1316-31,
1987
44.
Warner, SJ,
and
Libby P.
Human vascular smooth muscle cells. Target for and source of tumor necrosis factor.
J Immunol
142:
100-109,
1989[Abstract].
45.
Watanabe, N,
and
Kobayashi Y.
Selective release of a processed form of interleukin 1
.
Cytokine
6:
597-601,
1994[ISI][Medline].
46.
Wessendorf, JHM,
Garfinkel S,
Zhan X,
Brown S,
and
Maciag T.
Identification of a nuclear localization sequence within the structure of the human interleukin-1
precursor.
J Biol Chem
268:
22100-22104,
1993
47.
Yan, Z,
and
Hansson GK.
Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells.
Circ Res
82:
21-29,
1998
48.
Zhang, H,
Du Y,
Cohen RA,
Chobanian AV,
and
Brecher P.
Adventitia as a source of inducible nitric oxide synthase in the rat aorta.
Am J Hypertens
12:
467-475,
1999[ISI][Medline].
49.
Zola, H,
Flego L,
Wong YT,
Macardle PJ,
and
Kenney JS.
Direct demonstration of membrane IL-1
on the surface of circulating B lymphocytes and monocytes.
J Immunol
150:
1755-1762,
1993[Abstract].
This article has been cited by other articles:
![]() |
K. Schultz, V. Murthy, J. B. Tatro, and D. Beasley Endogenous interleukin-1{alpha} promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2927 - H2934. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Watarai, H. Warita, and K. Soma Effect of Nitric Oxide on the Recovery of the Hypofunctional Periodontal Ligament J. Dent. Res., April 1, 2004; 83(4): 338 - 342. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||